110 related articles for article (PubMed ID: 23238593)
1. TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases.
Deisseroth A; Tang Y; Zhang L; Akbulut H; Habib N
Cancer Gene Ther; 2013 Feb; 20(2):65-9. PubMed ID: 23238593
[TBL] [Abstract][Full Text] [Related]
2. Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.
Tang Y; Zhang L; Yuan J; Akbulut H; Maynard J; Linton PJ; Deisseroth A
Blood; 2004 Nov; 104(9):2704-13. PubMed ID: 15238426
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Deisseroth A
Mol Ther; 2008 Oct; 16(10):1753-60. PubMed ID: 18728641
[TBL] [Abstract][Full Text] [Related]
4. Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Deisseroth A
Gene Ther; 2010 Nov; 17(11):1333-40. PubMed ID: 20596057
[TBL] [Abstract][Full Text] [Related]
5. Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Zhang L; Deisseroth A
Mol Cancer Ther; 2006 Aug; 5(8):1975-85. PubMed ID: 16928818
[TBL] [Abstract][Full Text] [Related]
6. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.
Zhang L; Tang Y; Akbulut H; Zelterman D; Linton PJ; Deisseroth AB
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15101-6. PubMed ID: 14645711
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.
Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD
Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119
[TBL] [Abstract][Full Text] [Related]
8. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
[TBL] [Abstract][Full Text] [Related]
9. Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer.
Tang Y; Akbulut H; Maynard J; Petersen L; Fang X; Zhang WW; Xia X; Koziol J; Linton PJ; Deisseroth A
J Immunol; 2006 Oct; 177(8):5697-707. PubMed ID: 17015759
[TBL] [Abstract][Full Text] [Related]
10. Vector prime protein boost vaccination in the setting of myeloablative-induced lymphopenia suppresses growth of leukemia and solid tumors.
Han TH; Tang Y; Park YH; Maynard J; Li P; Akbulut H; Petersen L; Deisseroth A
Bone Marrow Transplant; 2010 Mar; 45(3):550-7. PubMed ID: 19648971
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
17. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
[TBL] [Abstract][Full Text] [Related]
19. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
[TBL] [Abstract][Full Text] [Related]
20. Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells.
Hoffmann TK; Meidenbauer N; Müller-Berghaus J; Storkus WJ; Whiteside TL
J Immunother; 2001; 24(2):162-71. PubMed ID: 11265774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
